Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI362 vs dulaglutide in type 2 diabetes mellitus
CTR20222740Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Nov 2022
- Modality
- Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mazdutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Innovent Biologics. Primary endpoint: Change in HbA1c from baseline at week 28. Started Nov 2022; status: completed.
02
Drugs
mazdutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20222740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222740.